Skip to main content

Table 2 Hardy-Weinberg analysis of studies examining the effect of FcGR3a genotype on outcome

From: A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer

FCGR3A genotype Actual frequency of genotypes (n) Expected frequency of genotypes (n) Hardy-Weinberg equilibrium x2 (1 degree of freedom) Genotyping methodology
  Musolino, 2008 (trastuzumab)    Nested PCR-based allele-specific restriction analysis assay
G/G (V/V) 11 10.67 0.03  
G/T (V/F) 26 26.67   
T/T (F/F) 17 16.67   
  Tamura, 2011 (trastuzumab) (Neoadjuvant group)    Goldengate genotyping
G/G (V/V) 7 6.67 0.15  
G/T (V/F) 6 6.67   
T/T (F/F) 2 1.67   
  Tamura, 2011 (trastuzumab)(Metastatic group)    Goldengate genotyping
G/G (V/V) 15 15.78 0.36  
G/T (V/F) 17 15.44   
T/T (F/F) 3 3.78   
  Hurvitz, 2011 (trastuzumab)    Nested PCR followed by Sanger sequencing (confirmed by MassARRAY)
G/G (V/V) 169 137.61 16.45  
G/T (V/F) 471 533.78   
T/T (F/F) 549 517.61   
  Cartron, 2002 (rituximab)    Nested PCR followed by allele-specific restriction enzyme digestion
G/G (V/V) 10 9 0.34  
G/T (V/F) 22 24   
T/T (F/F) 17 16   
  Weng, 2003 (rituximab)    Nested PCR followed by allele-specific restriction enzyme digestion. (confirmed by direct sequencing)
G/G (V/V) 13 12.52 0.05  
G/T (V/F) 40 40.97   
T/T (F/F) 34 33.52   
  Persky, 2012 (rituximab)    TaqMAN SNP Assay
G/G (V/V) 5 7.04 1.45  
G/T (V/F) 29 24.92   
T/T (F/F) 20 22.04   
  Kim, 2006 (rituximab)    Nested PCR followed by allele-specific restriction enzyme digestion
G/G (V/V) 53 56.64 2.74  
G/T (V/F) 54 46.73   
T/T (F/F) 6 9.64   
  Dornan, 2010 (rituximab)    Allele-specific PCR with SYBR Green
G/G (V/V) 49 53.07 1.0  
G/T (V/F) 202 192.6   
T/T (F/F) 168 172.7   
  Ghesquieres, 2012 (rituximab)    TaqMAN SNP Assay with specific fluorescent dye–labeled (FAM and VIC) MGB probes
G/G (V/V) 68 66.96 0.04  
G/T (V/F) 215 217.09   
T/T (F/F) 177 175.96   
  Carlotti, 2007 (rituximab)    PCR with fluorescent labeled probes followed by melt curve analysis
G/G (V/V) 17 17.2 0.01  
G/T (V/F) 46 45.59   
T/T (F/F) 30 30.2   
  Prochazka, 2011 (rituximab)    Nested PCR followed by allele-specific restriction enzyme digestion
G/G (V/V) 7 9.44 1.42  
G/T (V/F) 43 38.11   
T/T (F/F) 36 38.44   
  Bibeau, 2009 (cetuximab)    PCR followed by multiplex allele-specific PCR (SYBR Green fluorescence)
G/G (V/V) 10 14.59 5.02  
G/T (V/F) 43 33.82   
T/T (F/F) 15 19.59   
  Etienne-Grimaldi, 2012 (cetuximab)    Nested PCR followed by allele-specific restriction enzyme digestion
G/G (V/V) 6 6.71 0.19  
G/T (V/F) 25 23.58   
T/T (F/F) 20 20.71   
  Zhang, 2007 (cetuximab)    Allele-specific PCR
G/G (V/V) 5 4.11 0.44  
G/T (V/F) 14 15.77   
T/T (F/F) 16 15.11   
  Zhang, 2010 (cetuximab)    PCR – restriction fragment length polymorphism technique
G/G (V/V) 23 17.27 8.11  
G/T (V/F) 21 32.47   
T/T (F/F) 21 15.27   
  Dahan, 2011 (cetuximab)    PCR – restriction fragment length polymorphism technique
G/G (V/V) 6 4.57 0.88  
G/T (V/F) 20 22.86   
T/T (F/F) 30 28.57   
  Paez, 2010 (cetuximab)    48.48 dynamic array (BioMark system)
G/G (V/V) 16 12.81 1.89  
G/T (V/F) 41 47.38   
T/T (F/F) 47 43.81